Prognostic factors in avelumab maintenance therapy for metastatic urothelial carcinoma.

Kapar C, Özkan O, Eylemer Mocan E, Yaslikaya S, Tatlı AM, Akdağ G, Demir H, Bilgetekin I, Helvacı K, Selcukbiricik F, Köse F, Sari M, Erdem GU, İşleyen ZS, Arslan C, Celik S, Evrensel T, Durukan BM, Kazaz SN, Ozturk B, Çelik H, Özen M, Erel P, Şancı PC, Ergün Y, Taban H, Kuzu ÖF, Kahya BU, Arslan AM, Sakin A, Araz M, Okutur K, Akgül F, Mirili C, Sevinç A, Atalah F, Düzköprü Y, Gülbağcı B, Kandemir N, Kosku H, Aydın E, Erdem D, Guliyev M, Yılmaz M, Çulha Y, Şahin B, Gürsoy P, Erman M, Ürün Y, Tural D

Open source

DOI: 10.1080/1750743x.2026.2722548
Published: 2026 Sep 2
Container: Immunotherapy
Publisher: Not recorded
Open access: unknown

Credibility signals

limited evidence Score 43/100 under policy 1.0.0. This is a metadata assessment, not a judgment of the paper's conclusions.

Show all credibility signals

cautionDOI registered: No matching Crossref record was present in this response. Source: Crossref; license: CC0 metadata
cautionDOI resolves: No matching Crossref record was present in this response. Source: Crossref; license: CC0 metadata
not scoredDirectory of Open Access Journals: No matching DOAJ record was present in this response. No allow-list match; this is not evidence of low credibility. Source: DOAJ; license: CC0
not scoredMEDLINE indexed: Not checked or no result supplied; no credibility inference made. Source: No authority result supplied; license: Unknown
not scoredOpenAlex core source: Not checked or no result supplied; no credibility inference made. Source: No authority result supplied; license: Unknown
not scoredKnown publisher allow-list: Not checked or no result supplied; no credibility inference made. Source: No authority result supplied; license: Unknown
not scoredROR affiliation: Not checked or no result supplied; no credibility inference made. Source: No authority result supplied; license: Unknown
not scoredRetraction Watch retraction: No retraction notice matched this DOI in the deployed snapshot. No matching event found; coverage may be incomplete. Source: Retraction Watch; license: CC BY 4.0
not scoredRetraction Watch expression of concern: No expression of concern notice matched this DOI in the deployed snapshot. No matching event found; coverage may be incomplete. Source: Retraction Watch; license: CC BY 4.0
not scoredRetraction Watch correction: No correction notice matched this DOI in the deployed snapshot. No matching event found; coverage may be incomplete. Source: Retraction Watch; license: CC BY 4.0
not scoredRetraction Watch reinstatement: No reinstatement notice matched this DOI in the deployed snapshot. No matching event found; coverage may be incomplete. Source: Retraction Watch; license: CC BY 4.0
not scoredOpen access status: Not checked or no result supplied; no credibility inference made. Source: No authority result supplied; license: Unknown
not scoredPublication license: Not checked or no result supplied; no credibility inference made. Source: No authority result supplied; license: Unknown
not scoredPublication version: A publication version was supplied but is not scored. Source: Normalized work metadata; license: Caller-provided; provenance license not supplied to scorer
cautionMetadata completeness: 5 of 6 scored descriptive metadata groups are present; missing fields increase uncertainty. Source: Normalized work metadata; license: Caller-provided; provenance license not supplied to scorer

Cite this work

BibTeX

@article{allodium:10.1080/1750743x.2026.2722548,
  title = {Prognostic factors in avelumab maintenance therapy for metastatic urothelial carcinoma.},
  author = {Kapar C and Özkan O and Eylemer Mocan E and Yaslikaya S and Tatlı AM and Akdağ G and Demir H and Bilgetekin I and Helvacı K and Selcukbiricik F and Köse F and Sari M and Erdem GU and İşleyen ZS and Arslan C and Celik S and Evrensel T and Durukan BM and Kazaz SN and Ozturk B and Çelik H and Özen M and Erel P and Şancı PC and Ergün Y and Taban H and Kuzu ÖF and Kahya BU and Arslan AM and Sakin A and Araz M and Okutur K and Akgül F and Mirili C and Sevinç A and Atalah F and Düzköprü Y and Gülbağcı B and Kandemir N and Kosku H and Aydın E and Erdem D and Guliyev M and Yılmaz M and Çulha Y and Şahin B and Gürsoy P and Erman M and Ürün Y and Tural D},
  year = {2026},
  journal = {Immunotherapy},
  doi = {10.1080/1750743x.2026.2722548},
  url = {https://doi.org/10.1080/1750743x.2026.2722548}
}

RIS

TY  - JOUR
TI  - Prognostic factors in avelumab maintenance therapy for metastatic urothelial carcinoma.
AU  - Kapar C
AU  - Özkan O
AU  - Eylemer Mocan E
AU  - Yaslikaya S
AU  - Tatlı AM
AU  - Akdağ G
AU  - Demir H
AU  - Bilgetekin I
AU  - Helvacı K
AU  - Selcukbiricik F
AU  - Köse F
AU  - Sari M
AU  - Erdem GU
AU  - İşleyen ZS
AU  - Arslan C
AU  - Celik S
AU  - Evrensel T
AU  - Durukan BM
AU  - Kazaz SN
AU  - Ozturk B
AU  - Çelik H
AU  - Özen M
AU  - Erel P
AU  - Şancı PC
AU  - Ergün Y
AU  - Taban H
AU  - Kuzu ÖF
AU  - Kahya BU
AU  - Arslan AM
AU  - Sakin A
AU  - Araz M
AU  - Okutur K
AU  - Akgül F
AU  - Mirili C
AU  - Sevinç A
AU  - Atalah F
AU  - Düzköprü Y
AU  - Gülbağcı B
AU  - Kandemir N
AU  - Kosku H
AU  - Aydın E
AU  - Erdem D
AU  - Guliyev M
AU  - Yılmaz M
AU  - Çulha Y
AU  - Şahin B
AU  - Gürsoy P
AU  - Erman M
AU  - Ürün Y
AU  - Tural D
PY  - 2026
JO  - Immunotherapy
DO  - 10.1080/1750743x.2026.2722548
UR  - https://doi.org/10.1080/1750743x.2026.2722548
ER  -

APA

C, K., O, Ö., E, E. M., S, Y., AM, T., G, A., H, D., I, B., K, H., F, S., F, K., M, S., GU, E., ZS, İ., C, A., S, C., T, E., BM, D., SN, K., B, O., H, Ç., M, Ö., P, E., PC, Ş., Y, E., H, T., ÖF, K., BU, K., AM, A., A, S., M, A., K, O., F, A., C, M., A, S., F, A., Y, D., B, G., N, K., H, K., E, A., D, E., M, G., M, Y., Y, Ç., B, Ş., P, G., M, E., Y, Ü., & D, T. (2026). Prognostic factors in avelumab maintenance therapy for metastatic urothelial carcinoma.. Immunotherapy. https://doi.org/10.1080/1750743x.2026.2722548

Source records

pubmed · retrieved 2026-09-26T10:18:30.450Z